PANTHERx® Rare Pharmacy Expands Services to Include Dispensing AYVAKIT® (avapritinib) for the Expanded Approval for Treatment of Indolent Systemic Mastocytosis (ISM)
June 19, 2023 PITTSBURGH – Blueprint Medicines recently announced the approval of AYVAKIT® (avapritinib) for the expanded indication of adults with Indolent Systemic Mastocytosis (ISM). AYVAKIT was previously approved for the treatment of adults with...
Read More
PANTHERx® Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT® (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam
June 27, 2022 PITTSBURGH – PANTHERx® Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy distribution partner for DIACOMIT® (stiripentol). DIACOMIT is a new molecular entity approved by the FDA in 2018 for the adjunctive...
Read More
PANTHERx Rare Celebrates Fifth Patient Choice Award Win
May 4, 2022 PITTSBURGH – For a fifth time, PANTHERx® Rare has been recognized as the winner of the annual, Specialty Pharmacy Patient Choice Award™. Since 2016, the Managed Markets Insights & Technology Zitter Health Insight’s (MMIT ZHI) Patient Choice...
Read More
PANTHERx® Rare Selected by Aadi Bioscience to Distribute FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for advanced malignant perivascular epithelioid cell neoplasm (PEComa)
February 24, 2022 PANTHERx® Rare announces that it has been selected by Aadi Bioscience as the exclusive U.S. pharmacy distribution partner for new drug FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound). FYARRO, an...
Read More
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome
January 13, 2022 PANTHERx® Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev®...
Read More
2021 Marks Milestone Fourth Patient Choice Award for PANTHERx Rare
Read the Official PANTHERx Press Release. PANTHERx Rare has again been recognized as the winner of the annual, national Specialty Pharmacy Patient Choice Award™. “The results of the Managed Markets Insights & Technology Zitter Health Insights (MMIT...
Read More